IMCR — Immunocore Holdings Share News
0.000.00%
Last trade - 00:00- $1.54bn
- $1.05bn
- $400.02m
Brief: Immunocore Presents Kimmtrak Clinical Data Demonstrating That Patients With Stable Disease And Confirmed Tumor Reduction Have Similar Clinical Outcomes To Patients With Partial Response
Brief: Immunocore Reports Updated Phase 1 Data Of Brenetafusp (Imc-F106c), An Immtac Bispecific Targeting Prame, In Immune Checkpoint Pre-Treated Cutaneous Melanoma Patients At Asco 2024
Brief: Immunocore Converts Phase 2/3 TEBE-AM Clinical Trial Into Registrational Phase 3 Trial
Immunocore Holdings PLC reports results for the quarter ended in March - Earnings Summary
Immunocore Holdings PLC expected to post a loss of 37 cents a share - Earnings Preview
Brief: Immunocore Files For Mixed Shelf- SEC Filing
Immunocore Holdings PLC reports results for the quarter ended in December - Earnings Summary
Immunocore Holdings PLC expected to post a loss of 22 pence a share - Earnings Preview
Brief: Immunocore Announces Clinical Trial Collaboration And Supply Agreement With Bristol Myers Squibb
Brief: Immunocore Says Pricing Of $350.0 Mln Aggregate Principal Amount Of 2.50% Convertible Senior Notes Due 2030
U.S. STOCKS ON THE MOVE-Kura Oncology , Vertex Pharma, Nucor
U.S. STOCKS ON THE MOVE-SLB, Corning, 2seventy Bio
Immunocore slides on planned $300 mln convertible debt offering
Brief: Immunocore Expects To Report Prelim Unaudited Net Product Revenue From Sales Of Kimmtrak Of About $66 Mln For Q4
Brief: Immunocore Announces Proposed Convertible Senior Notes Offering
Brief: Immunocore Says Co Increasing Commercial Access to KIMMTRAK Globally
Immunocore Holdings PLC expected to post a loss of 29 pence a share - Earnings Preview
Brief: Immunocore Presents Three-Year Overall Survival Data From The Kimmtrak Phase 3 Trial
Immunocore Holdings PLC reports results for the quarter ended in June - Earnings Summary